MBRX – Moleculin Biotech Inc
Moleculin Biotech, Inc.MBRX
$0.67Name : Moleculin Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $9,465,425.00
EPSttm : -4.99
Moleculin Biotech, Inc.
$0.67
2.91%$0.0201Float Short %
7.01
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.69
EPS Last/This Y
1.04
EPS This/Next Y
0.43
Price
0.66
Target Price
10.67
Analyst Recom
1
Performance Q
-40.18
Relative Volume
1.22
Beta
1.57
Ticker: MBRX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-08 | MBRX | 0.9937 | N/A | N/A | 0 |
| 2025-05-09 | MBRX | 1.055 | N/A | N/A | 0 |
| 2025-05-12 | MBRX | 1.055 | N/A | N/A | 0 |
| 2025-05-13 | MBRX | 1.055 | N/A | N/A | 0 |
| 2025-05-14 | MBRX | 0.9987 | N/A | N/A | 0 |
| 2025-05-15 | MBRX | 0.899 | N/A | N/A | 0 |
| 2025-05-16 | MBRX | 0.9431 | N/A | N/A | 0 |
| 2025-05-19 | MBRX | 0.9756 | N/A | N/A | 0 |
| 2025-05-20 | MBRX | 0.97 | N/A | N/A | 0 |
| 2025-05-21 | MBRX | 0.9703 | N/A | N/A | 0 |
| 2025-05-22 | MBRX | 0.9492 | N/A | N/A | 0 |
| 2025-05-23 | MBRX | 0.9234 | N/A | N/A | 0 |
| 2025-05-27 | MBRX | 0.8918 | N/A | N/A | 0 |
| 2025-05-28 | MBRX | 0.8718 | N/A | N/A | 0 |
| 2025-05-29 | MBRX | 0.9017 | N/A | N/A | 0 |
| 2025-05-30 | MBRX | 0.8823 | N/A | N/A | 0 |
| 2025-06-02 | MBRX | 0.9001 | N/A | N/A | 0 |
| 2025-06-03 | MBRX | 0.8431 | N/A | N/A | 0 |
| 2025-06-04 | MBRX | 0.6675 | N/A | N/A | 0 |
| 2025-06-05 | MBRX | 0.69 | N/A | N/A | 0 |
| 2025-06-06 | MBRX | 0.67 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-08 | MBRX | 1.00 | - | - | -5.28 |
| 2025-05-09 | MBRX | 1.05 | - | - | -5.28 |
| 2025-05-12 | MBRX | 1.08 | - | - | -5.28 |
| 2025-05-13 | MBRX | 1.07 | - | - | -5.28 |
| 2025-05-14 | MBRX | 0.99 | - | - | -5.28 |
| 2025-05-15 | MBRX | 0.91 | - | - | -5.28 |
| 2025-05-16 | MBRX | 0.94 | - | - | -5.28 |
| 2025-05-19 | MBRX | 0.99 | - | - | -5.28 |
| 2025-05-20 | MBRX | 0.98 | - | - | -5.28 |
| 2025-05-21 | MBRX | 0.96 | - | - | -5.28 |
| 2025-05-22 | MBRX | 0.92 | - | - | -5.28 |
| 2025-05-23 | MBRX | 0.92 | - | - | -5.28 |
| 2025-05-27 | MBRX | 0.89 | - | - | -5.28 |
| 2025-05-28 | MBRX | 0.88 | - | - | -5.28 |
| 2025-05-29 | MBRX | 0.90 | - | - | -5.28 |
| 2025-05-30 | MBRX | 0.87 | - | - | -5.28 |
| 2025-06-02 | MBRX | 0.90 | - | - | -5.28 |
| 2025-06-03 | MBRX | 0.84 | - | - | -5.28 |
| 2025-06-04 | MBRX | 0.67 | - | - | -5.28 |
| 2025-06-05 | MBRX | 0.69 | - | - | -5.28 |
| 2025-06-06 | MBRX | 0.66 | - | - | -5.28 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-08 | MBRX | 0.00 | 1.02 | 3.32 |
| 2025-05-09 | MBRX | 0.00 | 1.02 | 3.32 |
| 2025-05-12 | MBRX | 0.00 | 1.09 | 5.18 |
| 2025-05-13 | MBRX | 0.00 | 1.09 | 5.18 |
| 2025-05-14 | MBRX | 0.00 | 1.09 | 5.18 |
| 2025-05-15 | MBRX | 0.00 | 1.09 | 5.18 |
| 2025-05-16 | MBRX | 0.00 | 1.09 | 5.18 |
| 2025-05-19 | MBRX | 0.00 | 1.15 | 5.18 |
| 2025-05-20 | MBRX | 0.00 | 1.15 | 5.18 |
| 2025-05-21 | MBRX | 0.00 | 1.15 | 5.18 |
| 2025-05-22 | MBRX | 0.00 | 1.15 | 5.18 |
| 2025-05-23 | MBRX | 0.00 | 1.15 | 5.18 |
| 2025-05-27 | MBRX | 0.00 | 0.99 | 5.18 |
| 2025-05-28 | MBRX | 0.00 | 0.99 | 7.01 |
| 2025-05-29 | MBRX | 0.00 | 0.99 | 7.01 |
| 2025-05-30 | MBRX | 0.00 | 0.99 | 7.01 |
| 2025-06-02 | MBRX | 0.00 | 0.99 | 7.01 |
| 2025-06-03 | MBRX | 0.00 | 0.99 | 7.01 |
| 2025-06-04 | MBRX | 0.00 | 0.99 | 7.01 |
| 2025-06-05 | MBRX | 0.00 | 0.99 | 7.01 |
| 2025-06-06 | MBRX | 0.00 | 0.99 | 7.01 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.69
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
0.99
Beta
1.57
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
2
Growth Score
20
Sentiment Score
10
Actual DrawDown %
99.5
Max Drawdown 5-Year %
-99.6
Target Price
10.67
P/E
Forward P/E
PEG
P/S
P/B
225.59
P/Free Cash Flow
EPS
-5.8
Average EPS Est. Cur. Y
-5.28
EPS Next Y. (Est.)
-4.85
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.22
Return on Equity vs Sector %
-55331.2
Return on Equity vs Industry %
-55313.2
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Moleculin Biotech, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 17
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 3 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia and in Phase 1B/2 clinical trials for soft tissue sarcoma metastasized to the lungs. The company is also developing a WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription, and to treat glioblastoma brain tumors and pancreatic cancer, including diffuse intrinsic pontine glioma (DIPG). In addition, it develops a WP1122 portfolio, including WP1122, WP1096, and WP1097 to exploit the uses of inhibitors of glycolysis, and to treat glioblastoma brain tumors and pancreatic cancer. The company has a research and license agreement with MD Anderson, as well as a license agreement with Animal Life Sciences, LLC (ALI). Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
stock quote shares MBRX – Moleculin Biotech Inc Stock Price stock today
news today MBRX – Moleculin Biotech Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MBRX – Moleculin Biotech Inc yahoo finance google finance
stock history MBRX – Moleculin Biotech Inc invest stock market
stock prices MBRX premarket after hours
ticker MBRX fair value insiders trading